Treatment of paediatric non-cystic fibrosis bronchiectasis

Bibliography

• COLE P: Recent Advances In Infection 3. In: Host-microbial interactions in chronic respiratory disease. Reeves DS, Geddes AM (Eds), Churchill Livingstone, Edinburgh, UK (1989):141.
   Google Scholar
• BARKER AF, BARDANA EJ Jr: Bronchiectasis: update of an orphan disease. Am. Rev Respic Dis. (1988) 137(4):969–978.
   PubMedGoogle Scholar
• FERKOL TW, DAVIS BD: Bronchiectasis and bronchiolitis obliterans. In: Pediatric respiratory medicine. Landau T (Ed.), Mosby, Inc., St. Louis, Missouri, USA (1999):784–792.
   Google Scholar
• PASTEUR MC, HELLIWELL SM, HOUGHTON SJ et al.: An investigation into causative factors in patients with bronchiectasis. Am. J. Respic Crit. Care Med. (2000) 162(4 Pt 1):1277–1284.
   Google Scholar
• ANGRILL J, AGUSTI C, DE CELIS R et al.: Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax (2002) 57(1):15–19.
   Google Scholar
• BARKER AF: Bronchiectasis. N Engl. Med. (2002) 346(18):1383–1393.
   PubMed Web of Science ®Google Scholar
• ••A review article outlining the progress inthe medical management of bronchiectasis.
   Google Scholar
• SCALA R, ARONNE D, PALUMBO U et al.: Prevalence, age distribution and aetiology of bronchiectasis: a retrospective study on 144 symptomatic patients. Monaldi Arch. Chest Dis. (2000) 55(2):101–105.
   PubMedGoogle Scholar
• EDWARDS EA, BYRNES CA: Paediatric bronchiectasis in the 21st century: Experience of a tertiary children's hospital in New Zealand. I Paediatr. Child Health (2003) 39(2):111–117.
   PubMed Web of Science ®Google Scholar
• KARAKOC GB, YILMAZ M, ALTINTAS DU, KENDIRLI SG: Bronchiectasis: still a problem. Pediatr. Pulmonol (2001) 32(2):175–178.
   PubMed Web of Science ®Google Scholar
• SINGLETON R, MORRIS A, REDDING G et al.: Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatr. Pulmonol (2000) 29(3):182–187.
   PubMed Web of Science ®Google Scholar
• CALLAHAN CW, REDDING GJ: Bronchiectasis in children: orphan disease or persistent problem? Pediatr. Pulmonol (2002) 33(6):492–496.
   PubMed Web of Science ®Google Scholar
• •Commentary on the current issues associated with childhood bronchiectasis.
   Google Scholar
• CHANG AB, GRIMWOOD K, MULHOLLAND EK, TORZILLO PJ: Bronchiectasis in indigenous children in remote Australian communities. Med. J. Aust. (2002) 177:200–204.
   PubMed Web of Science ®Google Scholar
• ••A detailed evidence-based approachtowards the management of childhood bronchiectasis.
   Google Scholar
• WYNN-WILLIAMS M: Observations on the treatment of bronchiectasis and its relation to prognosis. Tubercle (1957) 38:133–145.
   PubMedGoogle Scholar
• KEARNEY PJ, KERSHAW CR, STEVENSON PA: Bronchiectasis in acute leukaemia. Br. Med. J. (1977) 2:857.
   PubMedGoogle Scholar
• KNOWLES GK, STANHOPE R, GREEN M: Bronchiectasis complicating chronic lymphatic leukaemia with hypogammaglobulinaemia. Thorax (1980) 32:217.
   Google Scholar
• EIJKOUT HW, VAN DER MEER JW, KALLENBERG CG et al, Inter-University Working Party for the Study of Immune Deficiencies: The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann. Intern. Med. (2001) 135(3):165–174.
   Google Scholar
• LIESE JG, WINTERGERST U, TYMPNER KD, BELOHRADSKY BH: High versus low dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am. .1. Dis. Child. (1992) 146:335–339.
   PubMedGoogle Scholar
• ROIFMAN CM, LEVISON H, GELFAND EW: High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet (1987) 1:1075–1077.
   PubMed Web of Science ®Google Scholar
• ROIFMAN CM, SCHROEDER H, BERGER M et al: Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int. Immunopharmacol. (2003) 3(9):1325–1333.
   PubMed Web of Science ®Google Scholar
• ELLERMAN A, BISGAARD H: Longitudinal study of lung function in a cohort of primary ciliary dyskinesia. Eur. Respic J. (1997) 10(10):2376–2379.
   PubMed Web of Science ®Google Scholar
• HADFIELD PJ, ROWE-JONES JM, BUSH A, MACKAY IS: Treatment of otitis media with effusion in children with primary ciliary dyskinesia. Otolaryngol. (1997) 22(4):302–306.
   Google Scholar
• BUSH A, COLE P, HARIRI M et al.: Primary ciliary dyskinesia: diagnosis and standards of care. Eut: Respic .1. (1998) 12(0982–988.
   Google Scholar
• SHALE DJ, FAUX JA, LANE DJ: Trial of Ketoconazole in non-invasive pulmonary aspergillosis. Thorax (1987) 42:26–31.
   PubMed Web of Science ®Google Scholar
• WARK PA, HENSLEY MJ, SALTOS N, BOYLE MJ, TONEGUZZI RC, EPID GD: Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomised controlled trial. I. Allergy Gin. Immunol. (2003) 111(5):952–957.
   PubMed Web of Science ®Google Scholar
• STEVENS DA, SCHWARTZ HJ, LEE JY et al.: A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N. Engl. J. Med. (2000) 342(11):756–762.
   PubMed Web of Science ®Google Scholar
• WARK PAB, GIBSON PG, WILSON AJ: Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst. Rev (2004):1.
   Google Scholar
• SKOV M, MAIN KM, SILLESEN IB, MULLER J, KOCH C, LANNG S: Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide. Ear: Resp. I (2002) 20(1):127–133.
   PubMed Web of Science ®Google Scholar
• ELPHICK H, SOUTHERN K: Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst. Rev (2004):1.
   Google Scholar
• STEVENS DA, MOSS RB, KURUP VP et al.: Allergic bronchopulmonary aspergillosis in cystic fibrosis state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin. Infect. Dis. (2003) 37\(Suppl. 3):S225–S264.
   Google Scholar
• SHEIKH S, MADIRAJU K, STEINER P, RAO M: Bronchiectasis in pediatric AIDS. Chest (1997) 112(5):1202–1207.
   PubMed Web of Science ®Google Scholar
• COHEN M, SAHN SA: Bronchiectasis in systemic disease. Chest (1999) 116:1063–1074.
   PubMed Web of Science ®Google Scholar
• KONSTAN MW, STERN RC, DOERSHUK CF: Efficacy of the flutter device for airway mucus clearance in patients with cystic fibrosis. I Pediatr. (1994) 124:689–693.
   Google Scholar
• JONES AP, ROWE BH: Bronchopulmonary hygiene physical therapy for chronic obstructive pulmonary disease and bronchiectasis. Cochrane Database Syst. Rev (2004):1. 1481
   Google Scholar
• PRYOR JA: Physiotherapy for airway clearance in adults. Eur. Respir. J. (1999) 14(6):1418–1424.
   PubMed Web of Science ®Google Scholar
• BATEMAN JR, NEWMAN SP, DAUNT KM, SHEAHAN NE PAVIA D, CLARKE SW: Is cough as effective as chest physiotherapy in the removal of excessive tracheobronchial secretions? Thorax (1981) 36(9):683–687.
   PubMed Web of Science ®Google Scholar
• SUTTON PP, PAVIA D, BATEMEN JR, CLARKE SW: Chest physiotherapy. Eur. Respir: Dis. (1982) 63(3):188–201.
   Web of Science ®Google Scholar
• GONDOR M, NIXON PA, MUTICH R: Comparison of Flutter device and chest physical therapy in the treatment of cystic fibrosis pulmonary exacerbation. Pediatr. Pulmonol (1999) 28:255–260.
   PubMed Web of Science ®Google Scholar
• HOMNICK DN, ANDERSON K, MARKS JH: Comparison of the Flutter device to standard chest physiotherapy in hospitalized patients with cystic fibrosis. Chest (1998) 114:993–997.
   PubMed Web of Science ®Google Scholar
• MCILWAINE PM, WONG LTK, PEACOCK D: Long-term comparative trial of positive expiratory pressure versus positive expiratory pressure (flutter) physiotherapy in the treatent of cystic fibrosis. J. Pediatr. (2001) 138:845–850.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN EF, NEDERGAARD T, DAHL R: Long-term treatment of chronic bronchitis with positive expiratory pressure mask and chest physiotherapy. Chest (1990) 97(3):645–650.
   PubMed Web of Science ®Google Scholar
• THOMPSON CS, HARRISON S, ASHLEY J, DAY K, SMITH DL: Randomised crossover study of the Flutter device and the active cycle of breathing technique in non-cystic fibrosis bronchiectasis. Thorax (2002) 57(5):446–448.
   PubMed Web of Science ®Google Scholar
• O'NEILL B, BRADLEY JM, MCARDLE N, MACMAHON J: The current physiotherapy management of patients with bronchiectasis: a UK survey. Clin. Pract. (2002) 56(1):34–35.
   Google Scholar
• WARWICK WJ, HANSEN LG: The long-term effect of high-frequency chest compression therapy on pulmonary complications of cystic fibrosis. Paed. Pulmonol (1991) 11(3):265–271.
   PubMed Web of Science ®Google Scholar
• ARENS R, GOZAL D, OMLIN KJ et al: Comparison of high frequency chest compression and conventional chest physiotherapy in hospitalized patients with cystic fibrosis. Am. Resp. Crit. Care Med. (1994) 150(4):1154–1157.
   PubMed Web of Science ®Google Scholar
• KLUFT J, BEKER L, CASTAGNINO M, GAISERJ, CHANEY H, FINK RJ: A comparison of bronchial drainage treatments in cystic fibrosis. Paed. Pulmonol (1996) 22(4):271–274.
   PubMed Web of Science ®Google Scholar
• GRANT C, PATI A, TAN D, VOGEL S, AICKIN R, SCRAGG R: Ethnic comparisons of disease severity in children hospitalized with pneumonia in New Zealand. J. Paediam Child Health (2001) 37(1):32–37.
   PubMed Web of Science ®Google Scholar
• AKALIN F, KOROGLU TF, BAKAC S, DAGLI E: Effects of childhood bronchiectasis on cardiac functions. Pediatr. Int. (2003) 45(2):169–174.
   PubMed Web of Science ®Google Scholar
• SWAMINATHAN S, KUPPURAO KV, SOMU N, VIJAYAN VK: Reduced exercise capacity in non-cystic fibrosis bronchiectasis. Indian J. Pediatr. (2003) 70(7553–6).
   Google Scholar
• EDMUNDS J, MOSELEY B, SHARPLES D et al.: Lung function and exercise tolerance in bronchiectasis: is small airways disease an important component in bronchiectasis. Am. j Resp. Crit. Care Med. (2001) 163(5):A715.
   Google Scholar
• KOULOURIS NG, RETSOU S, KOSMAS EN et al.: Tidal expiratory flow limitation, dyspnoea and exercise capacity in patients with bilateral bronchiectasis. Eur. Respir. J. (2003) 21(5):743–748.
   PubMed Web of Science ®Google Scholar
• OZEROVITCH LJ, SHOEMARK AN, JONES P, WILSON R: Effects of extent of disease, FEV1 and exercise capacity on quality of life in bronchiectasis. Am. Resp. Crit. Care Med. (2003)167(7):A746.
   Google Scholar
• ORENSTEIN DM: Exercise testing in cystic fibrosis. Pediatr. Pulmonol (1998) 25(4):223–225.
   PubMed Web of Science ®Google Scholar
• SHAH AR, GOZAL D, KEENS TG: Determinants of aerobic and anaerobic exercise performance in cystic fibrosis. Am.Respir: Crit. Care Med. (1998) 157(4 Pt 1):1145–1150.
   Google Scholar
• NIXON PA, ORENSTEIN DM, KELSEY SF, DOERSHUK CF: The prognostic value of exercise testing in patients with cystic fibrosis. N Engl. J. Med. (1992) 327(25):1785–1788.
   PubMed Web of Science ®Google Scholar
• EDWARDS EA, NARANG I, LI A, HANSELL DM, ROSENTHAL M, BUSH A: HRCT chest features are not a surrogate for exercise limitation in bronchiectasis. Eur. Resp. (2004) (In Press).
   Google Scholar
• CYSTIC FIBROSIS TRUST, BRITISH PAEDIATRIC ASSOCIATION, BRITISH THORACIC SOCIETY: Clinical guidelines for cystic fibrosis care. Royal College of Physicians, London, UK (1996).
   Google Scholar
• BRADLEY J, MORAN F, GREENSTONE M: Physical training for bronchiectasis. Cochrane Database Syst. Rev (2004):1.
   Web of Science ®Google Scholar
• MORRIS P, CHANG A, GRIMWOOD K: Antibiotics for chronic suppurative lung disease in children. Cochrane Database Syst. Rev (2004):1.
   Google Scholar
• EVANS DJ, BARA Al, GREENSTONE M: Prolonged antibiotics for purulent bronchiectasis. Cochrane Database Syst. Rev. (2004):1.
   Web of Science ®Google Scholar
• CURRIE DC: Nebulism for bronchiectasis. Thorax (1997) 52\(Suppl. 2):572–574.
   Google Scholar
• HILL SL, STOCKLEY RA: Effect of short and long term antibiotic response on lung function in bronchiectasis. Thorax (1986) 41(10):798–800.
   PubMed Web of Science ®Google Scholar
• HILL SL, MORRISON HM, BURNETT D, STOCKLEY RA: Short term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high doses orally or by inhalation. Thorax (1986) 41(7):559–565.
   PubMed Web of Science ®Google Scholar
• EVANS DJ, GREENSTONE M: Long-term antibiotics in the management of non-CF bronchiectasis-do they improve outcome? Respir: Med. (2003) 97(7):851–858.
   Google Scholar
• FREDERIKSEN B, LANNG S, KOCH C, HOLBY N: Improved survival in the Danish center-treated cystic fibrosis patients: Results of aggressive treatment. Pediatr. Pulmonol (1996) 21(3):153–158.
   PubMed Web of Science ®Google Scholar
• ••A review of survival data of a Danish centretreating CF patients advocating early ana- l? aeruginosa treatment and regular admissions.
   Google Scholar
• CURRIE DC, GARBETT ND, CHAN KLet al.: Double-blind randomized study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis. Q. J. Med. (1990) 76(280):799–816.
   Google Scholar
• RAYNER CF, TILLOTSON G, COLE PJ, WILSON R: Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis. Antimicrob. Chemother: (1994) 34(1):149–156.
   Google Scholar
• MEDICAL RESEARCH COUNCIL: Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non-Tuberculous) Committee of the Medical Research Council. Br. Med. (1957) 2:255–259.
   PubMedGoogle Scholar
• EQUI A, BALFOUR-LYNN IM, BUSH A, ROSENTHAL M: Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet (2002) 360(9338):978–984.
   PubMed Web of Science ®Google Scholar
• GAREY KW, ALWANI A, DANZIGER DH, RUBINSTEIN I: Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases. Chest (2003) 123:261–265.
   PubMed Web of Science ®Google Scholar
• GORRINI M, LUPI A, VIGLIO S et al.: Inhibition of human neutrophil elastase by erythromycin and flurythromycon, two macrolide antibiotics. Am. I Resp. Grit. Care Med. (2001) 25(4):492–499.
   Google Scholar
• KUDCOH S, AZUMA A, YAMAMOTO M, IZUMI T, ANDO M: Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am. I Resp. Grit. Care Med. (1998) 157(6 Pt 1):1829–1832.
   Google Scholar
• KHAIR OA, DEVALIA JL, ABDELAZIZ MM, SAPSFORD RJ, DAVIES RJ: Effect of erythromycin on Haemophilus influenzae endotwdn-induced release of IL-6 IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eut: Respic (1995) 8(9):1451–1457.
   PubMed Web of Science ®Google Scholar
• TAKIZAWA H, DESAKI M, OHTOSHI T et al: Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am. J. Resp. Crit. Care Med. (1997) 156(1):266–271.
   PubMed Web of Science ®Google Scholar
• PRINCE AS: Biofilms, antimicrobial resistance, and airway infection. N Engl. .1. Med. (2002) 347(14):1110–1111.
   Google Scholar
• DOUCET-POPULAIRE F, BURIANKOVA K, WEISER J, PERNODET JL: Natural and acquired macrolide resistance in mycobacteria. CLIFF. Drug Targets Infect. Disord. (2002) 2(4):355–370.
   PubMedGoogle Scholar
• TSANG KW, HO PI, CHAN KN et al.: A pilot study of low-dose erythromycin in bronchiectasis. Ear: Respic J. (1999) 13(2):361–364.
   PubMed Web of Science ®Google Scholar
• KOH YY, LEE MH, SUN YH, SUNG KW, CHAE JH: Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo- controlled study. Eut: Respic J. (1997) 10(5):994–999.
   PubMed Web of Science ®Google Scholar
• MUKHOPADHYAY S, SINGH M, CATER JI, OGSTON S, FRANKLIN M, OLVER RE: Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Thorax (1996) 51:364–368.
   PubMed Web of Science ®Google Scholar
• LIN HC, CHENG HF, WANG CH, LIU CY, YU CT, KUO HP: Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. Am. J. Respic Grit. Care Med. (1997) 155(6):2024–2029.
   PubMed Web of Science ®Google Scholar
• ORRIOLS R, ROIG J, FERRER J et al: Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respic Med. (1999) 93(7):476–480.
   PubMed Web of Science ®Google Scholar
• BARKER AF, COUCH L, FIEL SB et al.: Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Am. I Resp. Grit. Care Med. (2000) 162(2 Pt 1):481–485.
   Google Scholar
• RAMSEY BW, PEPE MS, QUAN JM, OTTO KL, MONTGOMERY AB, WILLIAMS-WARREN J et al.: Intermittent administration of inhaled Tobramycin in patients with cystic fibrosis. N Engl. J. Med. (1999) 340(1):23–30.
   PubMed Web of Science ®Google Scholar
• RATJEN F, DORING G, NIKOLAIZIK WH: Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet (2001) 358(9286):983–984.
   PubMed Web of Science ®Google Scholar
• STOCKLEY RA, HILL SL, BURNETT D: Nebulized amoxicillin in chronic purulent bronchiectasis. Clin. The]: (1985) 7(5):593–599.
   PubMed Web of Science ®Google Scholar
• RAM FSF, WELLS A, KOLBE J: Inhaled steroids for bronchiectasis. Cochrane Database Syst. Rev (2004):1.
   Web of Science ®Google Scholar
• ELBORN JS, JOHNSTON B, ALLEN F, CLARKE J, MCGARRY J, VARGHESE G: Inhaled steroids in patients with bronchiectasis. Respic Med. (1992) 86(2):121–124.
   PubMed Web of Science ®Google Scholar
• TSANG KW, HO PL, LAM WK et al: Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am. I Respic Crit. Care Med. (1998) 158(3):723–727.
   PubMed Web of Science ®Google Scholar
• LASSERSON T, HOLT K, GREENSTONE M: Oral steroids for bronchiectasis (stable and acute exacerbations). Cochrane Database Syst. Rev (2004):1.
   Google Scholar
• PETERS-GOLDEN M: Pulmonary diseases other than asthma as potential targets for antileukotriene therapy. Gin. Rev Allergy Immunol (1999) 17(1-2):247–260.
   PubMed Web of Science ®Google Scholar
• CORLESS JA, WARBURTON CJ: Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis. Cochrane Database Syst. Rev (2004):1.
   Google Scholar
• LLELEWELLYN-JONES CG, JOHNSON MM, MITCHELL JL et at In vivo study of indomethacin in bronchiectasis: effect on neutrophil function and lung secretion. Ear: Respic I (1995) 8(9):1479–1487.
   PubMed Web of Science ®Google Scholar
• TAMAOKI J, CHIYOTANI A, KOBAYASHI K, SAKAI N, KANEMURA T, TAKIZAWA T: Effect of indomethacin on bronchorrhea in patients with chronic bronchitis, diffuse panbronchiolitis, or bronchiectasis. Am. Rev. Respic Dis. (1992) 145(3):548–552.
   PubMed Web of Science ®Google Scholar
• STEELE K, LASSERSON JA, GREENSTONE M: Oral methyl-xanthines for bronchiectasis. Cochrane Database Syst. Rev (2004):1.
   Google Scholar
• FRANCO F, SEIKH A, GREENSTONE M: Short acting beta-2 agonists for bronchiectasis. Cochrane Database Syste. Rev (2004):1.
   Google Scholar
• SHEIKH A, NOLAN D, GREENSTONE M: Long-acting beta-2-agonists for bronchiectasis. Cochrane Database Syst. Rev (2004):1.
   Google Scholar
• LASSERSON T, HOLT K, EVANS DJ, GREENSTONE M: Anticholinergic therapy for bronchiectasis. Cochrane Database Syst. Rev (2004):1.
   Google Scholar
• CROCKETT AJ, CRANSTON JM, LATIMER KM, ALPERS JH: Mucolytics for bronchiectasis. Cochrane Database Syst. Rev (2004):1.
   Google Scholar
• OLIVIERI D, CIACCIA A, MARANGIO E, MARISCO S, TODISCO T, DEL VITA M: Role of bromhexine in exacerbations of bronchiectasis. Respiration (1991) 58:117–121.
   PubMed Web of Science ®Google Scholar
• DUIJVESTIJN YC, BRAND PL: Systematic review of N-acetylcysteine in cystic fibrosis. Acta Paediatr. (1999) 88(1):38–41. too. O'DONNELL AE, BARKER AF, ILOWITE JS, FICK RB: Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest (1998) 113(5):1329–1334.
   Google Scholar
• DAVIAKAS E, ANDERSON SD, EBERL S, CHAN HK, BAUTOVICH G: The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest (2001) 119:414–421.
   PubMed Web of Science ®Google Scholar
• DAVISKAS E, ANDERSON SD, EBERL S, CHAN HK, BAUTOVICH G: Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am. Respir. Crit. Care Med. (1999) 159(6):1843–1848.
   PubMed Web of Science ®Google Scholar
• WILLS P, GREENSTONE M: Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst. Rev (2004):1.
   Web of Science ®Google Scholar
• CAMPBELL DN, LILLY JR: The changing spectrum of pulmonary operations in infants and children. J. Thome. Cardiovasc. Surg. (1982) 83(5):680–685.
   PubMed Web of Science ®Google Scholar
• ADEBONOJO SA, GRILLO IA, OSINOWO O, ADEBO OA: Suppurative diseases of the lung and pleura: a continuing challenge in developing countries. Ann. Thorac. Surg. (1982) 33(1):40–47.
   PubMed Web of Science ®Google Scholar
• CORLESS JA, WARBURTON CJ: Surgery versus non-surgical treatment for bronchiectasis. Cochrane Database Syst. Rev (2004)1.
   Web of Science ®Google Scholar
• AGASTHIAN T, DESCHAMPS C, TRASTEK VF, ALLEN MS, PAIROLERO PC: Surgical management of bronchiectasis. Ann. Thorac. Surg. (1996) 62(4):976–978.
   PubMed Web of Science ®Google Scholar
• KUTLAY H, CANGIR AK, ENON S et al.: Surgical treatment of bronchiectasis: analysis of 166 patients. Eur: Cardiothorac. Surg. (2002) 21(4):634–637.
   PubMed Web of Science ®Google Scholar
• SMIT HJ, SCHREURS AJ, VAN DEN BOSCH JM, WESTERMANN CJ: Is resection of bronchiectasis beneficial in patients with primary ciliary dyskinesia? Chest (1996) 109(6):1541–1544.
   PubMed Web of Science ®Google Scholar
• MAZIERES J, MURRIS M, DIDIER A et al.: Limited operation for severe multisegmental bilateral bronchiectasis. Ann. Thorac. Surg. (2003) 75(2):382–387.
   PubMed Web of Science ®Google Scholar
• EDMUNDS J, PASTEUR M, TAYLOR A: Investigation and management of bronchiectasis at a specialist clinic improves pulmonary function. Am. I Resp. Crit. Care Med. (1999) 10(Suppl.):D92.
   Google Scholar
• FRENCH J, BILTON D, CAMPBELL F: Nurse specialist care for bronchiectasis. Cochrane Database Syst. Rev (2004):1.
   Google Scholar
• SHARPLES LD, EDMUNDS J, BILTON D et al.: A randomised controlled trial of nurse practitioner versus doctor led outpatient care in a bronchiectasis clinic. Thorax (2002) 57(8):661–666.
   PubMed Web of Science ®Google Scholar
• KELLY MG, MURPHY S, ELBORN JS: Bronchiectasis in secondary care: a comprehensive profile of a neglected disease. Eur. J. Intern. Med. (2003) 14:488–492.
   PubMedGoogle Scholar
• SAYNAJAKANGAS O, KEISTINEN T, TUUPONEN T, KIVELA SL: The course of childhood bronchiectasis: a case report and considerations of hospital use. Int. J. Circumpolar Health (1998) 57(4):276–279.
   PubMedGoogle Scholar
• FIELD CE: Bronchiectasis in childhood. Pediatrics (1949) 4(Part I):21-46; Part II: 231–248; Part III: 355–372.
   Google Scholar
• STRANG C: The fate of children with bronchiectasis. Ann. Intern. Med. (1956) 44:630–656.
   PubMed Web of Science ®Google Scholar
• AVERY ME, RILEY MC, WEISS A: The course of childhood bronchiectasis. Bull. Johns Hopk. Hosp. (1961) 109:20–34.
   PubMedGoogle Scholar
• CLARK S: Bronchiectasis in childhood. Br. Med. J. (1963) 1:80–88.
   PubMed Web of Science ®Google Scholar
• GLAUSER EM, COOK CD, HARRIS GB: Bronchiectasis: a review of 187 cases in children with follow-up pulmonary function studies in 58. Acta Paediam. Scand. (1966) 165 (Suppl.) :1–16.
   Google Scholar
• FLESHMAN JK, WILSON JF, COHEN JJ: Bronchiectasis in Alaska Native children. (1968):517–523.
   Google Scholar
• CHANG AB, MASEL JP, BOYCE NC, WHEATON G, TORZILLO PJ: Non-CF bronchiectasis: Clinical and HRCT evaluation. Pediatr. Pulmonol. (2003) 35(6):477–483.
   PubMed Web of Science ®Google Scholar